Inflammatory Bowel Disease Patients
Conditions
Brief summary
To assess the prevalance of non\_alcoholic fatty liver diseases in inflammatory bowel disease patients and its relation to type of treatment given and disease severity
Detailed description
Inflammatory bowel diseases (IBD) including Crohns disease (CD) and ulcerative colitis (UC) are chronic relapsing disorders that often require long-term therapy and follow up . They are recognized for their complex pathophysiology that involves innate immune system deregulation and altered microbiome in genetically predisposed individuals. Non-alcoholic fatty liver disease (NAFLD) includes a wide spectrum of disorders, ranging from hepatic steatosis (NAFL) to non-alcoholic steatohepatitis (NASH). NAFLD patients are at high risk for liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Also NAFLD is typically associated with altered metabolism and metabolic syndrome (MetS).
Interventions
None listed
Sponsors
Assiut University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Crohn's disease (CD) patients * ulcerative colitis (UC) patients
Exclusion criteria
* diabetic patients * BMI equal and more than 30.0-34.9(class I obesity)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the prevalance of non-alcoholic fatty liver in inflammatory bowel disease participants | one year | u/s will be done to all participants of inflammatory bowel disease to asses the rate of non-alcoholic fatty liver affection of all patients |
Secondary
| Measure | Time frame |
|---|---|
| the Correlation between immunosuppressive drugs and prevalance of non-alcoholic fatty liver affection in inflammatory bowel disease participants | one year |
Contacts
Primary ContactShymaa A Ahmed, Resident
Backup ContactMohamed A Ali, Assistant professor
Outcome results
None listed